Verrica Pharmaceuticals, focused on dermatologic therapeutics, reported continued commercialization of its FDA-approved drug-device combination YCANTH (VP-102) for molluscum contagiosum with an expanding specialty sales force and broad insurance coverage. The company’s financial position shows constrained liquidity managed through a new secured credit agreement with restrictive covenants tied to YCANTH revenue and cash levels. Verrica’s clinical pipeline includes ongoing development of YCANTH for common warts and VP-315 for basal cell carcinoma, positioning it within a niche biotech dermatology market that relies heavily on regulatory approval, reimbursement, and commercial execution. Key risks include debt covenant compliance, funding R&D pipeline progression, and manufacturing dependencies. Upcoming milestones will center on achieving revenue thresholds, executing clinical trials, and expanding geographic partnerships.